<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03066804</url>
  </required_header>
  <id_info>
    <org_study_id>CLCZ696D2302</org_study_id>
    <secondary_id>2016-003410-28</secondary_id>
    <nct_id>NCT03066804</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind Controlled Study Comparing LCZ696 to Medical Therapy for Comorbidities in HFpEF Patients</brief_title>
  <acronym>PARALLAX</acronym>
  <official_title>A 24-week, Randomized, Double-blind, Multi-center, Parallel LCZ696 on NT-proBNP, Exercise Capacity, Symptoms and Safety Compared to Individualized Medical Management of Comorbidities in Patients With Heart Failure and Preserved Ejection Fraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the superiority of LCZ696 over individualized&#xD;
      medical therapy for comorbidities in reducing N-terminal pro-brain natriuretic peptide&#xD;
      (NT-proBNP) and improving exercise capacity and HF symptoms in patients with heart failure&#xD;
      with preserved ejection fraction (HFpEF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study was a 24-week, randomized, double-blind, multi-center, parallel group, active&#xD;
      controlled study to evaluate sacubitril/valsartan compared to individualized medical therapy&#xD;
      on NT proBNP, exercise capacity, symptoms and QoL in patients with heart failure and&#xD;
      preserved left ventricular ejection (HFpEF) fraction (LVEF &gt; 40%). Patients were initially&#xD;
      stratified into one of three strata according to prior treatment for comorbidities:&#xD;
      Angiotensin converting enzyme inhibitor (ACEi), angiotensin receptor blocker (ARB) or no&#xD;
      prior renin angiotensin system inhibitors (RASi). Patients in each stratum were randomized in&#xD;
      a 1:1 ratio and received either sacubitril/valsartan or comparator (i.e.&#xD;
&#xD;
      enalapril for patients in ACEi strata, valsartan for patients in the ARB strata and placebo&#xD;
      for patients in the No RASi strata). There was no designated proportion of patients planned&#xD;
      in each stratum; the strata were populated based upon the patient's prior treatment regimen.&#xD;
      The study consisted of a screening epoch of up to 2 weeks and a randomized treatment epoch of&#xD;
      24 weeks, which included a 1 to 4 week study drug up-titration epoch followed by a 20 to 23&#xD;
      week maintenance epoch. Uptitration to target doses was recommended to occur within the first&#xD;
      four weeks of the study, and was performed by Investigator's discretion based on the&#xD;
      patient's clinical status.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Actual">October 28, 2019</completion_date>
  <primary_completion_date type="Actual">October 28, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12</measure>
    <time_frame>Baseline, week 12</time_frame>
    <description>To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24</measure>
    <time_frame>Baseline, week 24</time_frame>
    <description>Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in NYHA Functional Class at Week 24</measure>
    <time_frame>Baseline, week 24</time_frame>
    <description>NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time.&#xD;
Class I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest&#xD;
The NYHA class change will be analyzed as a three category ordinal variable with levels: &quot;improved&quot;, &quot;unchanged&quot;, and &quot;worsened&quot;, defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24</measure>
    <time_frame>Baseline, Week 24</time_frame>
    <description>The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 &quot;worst&quot;-100 &quot;best&quot;).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2572</enrollment>
  <condition>Heart Failure With Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>sacubitril/valsartan (LCZ696)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients who fulfill the inclusion/exclusion criteria will be stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi. Patients in the ACEi strata will receive LCZ696 or enalapril. Patients in the ARB strata will receive LCZ696 or valsartan. Patients in the no RASi strata will receive LCZ696 or matching placebo.&#xD;
Patients in the ACEi and ARB strata will take two pills twice daily for each dose: one tablet from the LCZ696 pack and one tablet from the comparator pack. Patients in the no RASi strata will take only one tablet twice daily (LCZ696 or matching placebo).&#xD;
In the LCZ696 arm, patients will receive active LCZ696 in titrated doses from level 1 up to level 3 (50 mg, 100 mg and 200 mg twice daily orally).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to the comparator arm will receive either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).&#xD;
Patients in the ACE stratum randomized to comparator, will receive enalapril in titrated doses from level 1 up to level 3 (2.5 mg, 5 mg and 10 mg twice daily).&#xD;
Patients in the ARB stratum randomized to comparator will receive valsartan in titrated doses from level 1 up to level 3 (40 mg , 80 mg and 160 mg twice daily).&#xD;
Patients in the no RASi stratum randomized to comparator will receive LCZ696 matching placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sacubitril/valsartan</intervention_name>
    <description>Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally</description>
    <arm_group_label>sacubitril/valsartan (LCZ696)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enalapril</intervention_name>
    <description>Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan</intervention_name>
    <description>Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match sacubitril/valsartan</intervention_name>
    <description>Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match enalapril</intervention_name>
    <description>Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally</description>
    <arm_group_label>sacubitril/valsartan (LCZ696)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo to match valsartan</intervention_name>
    <description>Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally</description>
    <arm_group_label>sacubitril/valsartan (LCZ696)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;40% by echo within 6 months prior to study&#xD;
             entry or during the screening epoch&#xD;
&#xD;
          -  Symptom(s) of heart failure (HF) requiring treatment with diuretics (including loop,&#xD;
             or thiazide diuretics, or mineralocorticoid antagonist [MRAs]) for at least 30 days&#xD;
             prior to study entry&#xD;
&#xD;
          -  NYHA class II-IV&#xD;
&#xD;
          -  Structural heart disease (left atrial enlargement or left ventricular hypertrophy)&#xD;
             documented by echocardiogram.&#xD;
&#xD;
          -  NT-proBNP &gt; 220 pg/mL for patients with no atrial fibrillation/atrial flutter (AF) or&#xD;
             &gt;600 pg/mL for patients with AF&#xD;
&#xD;
          -  KCCQ clinical summary score &lt; 75&#xD;
&#xD;
          -  Patients on ACEi or ARB therapy must have a history of HTN&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior measurement of LVEF ≤ 40%, under stable conditions&#xD;
&#xD;
          -  Acute coronary syndrome (including MI), cardiac surgery, other major CV surgery within&#xD;
             3 months , or urgent percutaneous coronary intervention (PCI) within 3 months or an&#xD;
             elective PCI within 30 days prior to study entry&#xD;
&#xD;
          -  Any clinical event within the 6 months prior to Visit 1 that could have reduced the&#xD;
             LVEF (eg MI, coronary artery bypass graft [CABG]), unless an echo measurement was&#xD;
             performed after the event confirming the LVEF to be &gt;40%&#xD;
&#xD;
          -  Current (within 30 days from Visit 1) acute decompensated HF requiring therapy.&#xD;
&#xD;
          -  Current (within 30 days from Visit 1) use of renin inhibitor(s), dual RAS blockade or&#xD;
             LCZ696&#xD;
&#xD;
          -  History of hypersensitivity to LCZ696 or its components&#xD;
&#xD;
          -  Patients with a known history of angioedema&#xD;
&#xD;
          -  Walk distance primarily limited by non-cardiac comorbid conditions at study entry&#xD;
&#xD;
          -  Alternative reason for shortness of breath such as: significant pulmonary disease or&#xD;
             severe COPD, hemoglobin (Hgb) &lt;10 g/dL males and &lt; 9.5 g/dL females, or body mass&#xD;
             index (BMI) &gt; 40 kg/m^2.&#xD;
&#xD;
          -  Systolic blood pressure (SBP) ≥ 180 mmHg at study entry, or SBP &gt;150 mmHg and &lt;180&#xD;
             mmHg at study entry unless the patient is receiving 3 or more antihypertensive drugs,&#xD;
             or SBP &lt; 110 mmHg at study entry.&#xD;
&#xD;
          -  Patients with HbA1c &gt; 7.5% not treated for diabetes&#xD;
&#xD;
          -  Patients with prior major organ transplant or intent to transplant (ie on transplant&#xD;
             list)&#xD;
&#xD;
          -  eGFR &lt; 30 ml/min/1.73 m^2 as measured by MDRD at screening&#xD;
&#xD;
          -  Serum potassium &gt; 5.2 mmol /L (or equivalent plasma potassium value) at study entry&#xD;
&#xD;
          -  History or presence of any other disease with a life expectancy of &lt; 3 years&#xD;
&#xD;
          -  Pregnant or nursing women or women of child-bearing potential unless they are using&#xD;
             highly effective methods of contraception&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Andalusia</city>
        <state>Alabama</state>
        <zip>36420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <zip>92704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sylmar</city>
        <state>California</state>
        <zip>91342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <zip>06905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33312</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thomasville</city>
        <state>Georgia</state>
        <zip>31792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <zip>60004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alexandria</city>
        <state>Louisiana</state>
        <zip>71301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chalmette</city>
        <state>Louisiana</state>
        <zip>70043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houma</city>
        <state>Louisiana</state>
        <zip>70360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68526</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <zip>43302</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corvallis</city>
        <state>Oregon</state>
        <zip>97330</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Abington</city>
        <state>Pennsylvania</state>
        <zip>19001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <zip>57104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>75904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1280AEB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878GEG</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Posadas</city>
        <state>Misiones</state>
        <zip>N3300AHX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ciudad de Salta</city>
        <state>Provincia De Salta</state>
        <zip>A4406BPF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tucuman</city>
        <state>San Miguel De Tucuman</state>
        <zip>T4000ICL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000DSV</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000IFL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Buenos Aires</city>
        <zip>C1430EGF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000AAW</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000EVQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5004BAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <zip>X5006CBI</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Formosa</city>
        <zip>P3600</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis</city>
        <zip>D5702JRS</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>3080</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S2200</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Santa Fe</city>
        <zip>S3000FWO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braunau</city>
        <zip>A5280</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Graz</city>
        <zip>A-8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hall in Tirol</city>
        <zip>6060</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heusden-Zolder</city>
        <zip>3550</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huy</city>
        <zip>4500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fortaleza</city>
        <state>CE</state>
        <zip>60430 370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74223-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Goiania</city>
        <state>GO</state>
        <zip>74605 050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30140 062</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belo Horizonte</city>
        <state>MG</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80230 130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Canoas</city>
        <state>Rio Grande Do Sul</state>
        <zip>92425 900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90880-480</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Blumenau</city>
        <state>SC</state>
        <zip>89010 500</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <zip>13060 080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ribeirao Preto</city>
        <state>SP</state>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15015-750</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sao Jose do Rio Preto</city>
        <state>SP</state>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Burgas</city>
        <zip>8018</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pazardzhik</city>
        <zip>4400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pernik</city>
        <zip>2300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shumen</city>
        <zip>9700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1G 1A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oakville</city>
        <state>Ontario</state>
        <zip>L6K 3W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St-Georges Beauce</city>
        <state>Quebec</state>
        <zip>G5Y 4T8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>050036</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cali</city>
        <state>Valle Del Cauca</state>
        <zip>760001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monteria</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Gil</city>
        <zip>684031</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brandys nad Labem</city>
        <state>Czech Republic</state>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brno</city>
        <state>Czech Republic</state>
        <zip>60200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cesky Krumlov</city>
        <state>Czech Republic</state>
        <zip>381 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <state>Czech Republic</state>
        <zip>466 60</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kromeriz</city>
        <state>Czech Republic</state>
        <zip>767 55</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liberec</city>
        <state>Czech Republic</state>
        <zip>46063</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louny</city>
        <state>Czech Republic</state>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pardubice</city>
        <state>Czech Republic</state>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Plzen</city>
        <state>Czech Republic</state>
        <zip>30100</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svitavy</city>
        <state>Czech Republic</state>
        <zip>568 25</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tabor</city>
        <state>Czech Republic</state>
        <zip>39003</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trebic</city>
        <state>Czech Republic</state>
        <zip>674 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>JIhlava</city>
        <state>CZE</state>
        <zip>58633</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Policska</city>
        <state>CZE</state>
        <zip>57201</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kolin</city>
        <zip>280 20</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Olomouc Lazce</city>
        <zip>77900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Prerov</city>
        <zip>751 52</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valasske Mezirici</city>
        <zip>75742</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Copenhagen NV</city>
        <zip>DK-2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Randers</city>
        <zip>8930</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Besancon cedex</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chambray les Tours</city>
        <zip>37170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Le Kremlin Bicetre</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Limoges cedex</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tourcoing</city>
        <zip>59200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valenciennes</city>
        <zip>59300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Regensburg</city>
        <state>Bavaria</state>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <state>DEU</state>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Detmold</city>
        <state>NRW</state>
        <zip>32756</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Homburg</city>
        <zip>61348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin Buch</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>12683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>D 10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bielefeld</city>
        <zip>33604</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bochum Wattenscheid</city>
        <zip>44866</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Brueel</city>
        <zip>19412</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chemnitz</city>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Coburg</city>
        <zip>96450</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dortmund</city>
        <zip>44379</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Elsterwerda</city>
        <zip>04910</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Erfurt</city>
        <zip>99097</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Essen</city>
        <zip>45277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60594</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>65929</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fuerth</city>
        <zip>90766</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fulda</city>
        <zip>36037</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle Saale</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hassloch</city>
        <zip>67454</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln-Nippes</city>
        <zip>50733</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koln</city>
        <zip>D-51065</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lubeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lüneburg</city>
        <zip>21339</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mainz</city>
        <zip>55116</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68165</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muehldorf</city>
        <zip>84453</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Munich</city>
        <zip>80638</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Neuruppin</city>
        <zip>16816</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nienburg</city>
        <zip>31582</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nuremberg</city>
        <zip>90402</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Papenburg</city>
        <zip>26871</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Potsdam</city>
        <zip>14471</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riesa</city>
        <zip>01589</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostock</city>
        <zip>18107</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rotenburg an der Fulda</city>
        <zip>36199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ruesselsheim</city>
        <zip>65428</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Schwaebisch Hall</city>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Siegen</city>
        <zip>57072</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stadtlohn</city>
        <zip>48703</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89077</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wallerfing</city>
        <zip>94574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wedel</city>
        <zip>22880</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wismar</city>
        <zip>23966</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01001</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01011</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala City</city>
        <zip>01015</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guatemala</city>
        <zip>01010</zip>
        <country>Guatemala</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <state>HUN</state>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mosanmagyarovar</city>
        <zip>9200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110 060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380 060</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manipal</city>
        <state>Karnataka</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440009</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashik</city>
        <state>Maharashtra</state>
        <zip>422005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashik</city>
        <state>Maharastra</state>
        <zip>422007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bikaner</city>
        <state>Rajasthan</state>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucknow</city>
        <state>Uttar Pradesh</state>
        <zip>226003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>India</city>
        <zip>560040</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashkelon</city>
        <zip>78278</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Be'er Sheva</city>
        <zip>84101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hadera</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Haifa</city>
        <zip>310 9601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rehovot</city>
        <zip>76100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cortona</city>
        <state>AR</state>
        <zip>52044</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sesto San Giovanni</city>
        <state>MI</state>
        <zip>20099</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rovigo</city>
        <state>RO</state>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sassari</city>
        <state>SS</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Vito al Tagliamento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Liepaja</city>
        <state>LVA</state>
        <zip>3401</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ogre</city>
        <zip>5001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <state>LTU</state>
        <zip>LT 50161</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>47144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44670</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Queretaro</city>
        <zip>76000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78200</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Almelo</city>
        <zip>7609 PP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Deventer</city>
        <zip>7416 SE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Doetinchem</city>
        <zip>7009 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gouda</city>
        <zip>2803 HH</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hardenberg</city>
        <zip>7770 AA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500 HB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stadskanaal</city>
        <zip>9501 HE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tilburg</city>
        <zip>5022 GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Venlo</city>
        <zip>5912 BL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trujillo</city>
        <state>La Libertad</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cercado De Lima</city>
        <state>Lima</state>
        <zip>01</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jesus Maria</city>
        <state>Lima</state>
        <zip>11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Borja</city>
        <state>Lima</state>
        <zip>41</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Isidro</city>
        <state>Lima</state>
        <zip>27</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Miguel</city>
        <state>Lima</state>
        <zip>32</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Callao</city>
        <zip>CALLAO 2</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Braga</city>
        <zip>4710243</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1495 005</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1500 650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lisboa</city>
        <zip>1600190</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Penafiel</city>
        <zip>4564-007</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Porto</city>
        <zip>4099-001</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Viana do Castelo</city>
        <zip>4901858</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vila Real</city>
        <zip>5000-508</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <state>District 4</state>
        <zip>4204179</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300041</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <state>Timis</state>
        <zip>300362</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bacau</city>
        <zip>600114</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Baia Mare</city>
        <zip>430123</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucharest</city>
        <zip>021659</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>022328</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>062272</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <zip>200642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craiova</city>
        <zip>200931</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pitesti</city>
        <zip>110084</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540142</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Targu Mures</city>
        <zip>540143</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300736</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tirgoviste</city>
        <zip>130095</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620028</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gatchina</city>
        <zip>188300</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>101953</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117292</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>117556</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>121309</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moscow</city>
        <zip>129301</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nizhnii Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Perm</city>
        <zip>614097</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rostov on Don</city>
        <zip>344068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>191144</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>191015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>197376</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tyumen</city>
        <zip>625026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Belgrade</city>
        <zip>11 000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kragujevac</city>
        <zip>34000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niska Banja</city>
        <zip>18205</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nis</city>
        <zip>18000</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sremska Kamenica</city>
        <zip>21204</zip>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Namestovo</city>
        <state>Slovak Republic</state>
        <zip>02901</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <state>Slovak Republic</state>
        <zip>080 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <state>SVK</state>
        <zip>81108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Handlova</city>
        <state>SVK</state>
        <zip>97251</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <zip>085 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bardejov</city>
        <zip>08501</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>821 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bratislava</city>
        <zip>842 31</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dolny Kubin</city>
        <zip>026 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lucenec</city>
        <zip>98439</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moldava nad Bodvou</city>
        <zip>045 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nitra</city>
        <zip>949 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>94002</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Povazska Bystrica</city>
        <zip>01701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Snina</city>
        <zip>09601</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Svidnik</city>
        <zip>089 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Trnava</city>
        <zip>91701</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cordoba</city>
        <state>Andalucia</state>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Huelva</city>
        <state>Andalucia</state>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Malaga</city>
        <state>Andalucia</state>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Puerto Real</city>
        <state>Cadiz</state>
        <zip>11510</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Villamartin</city>
        <state>Cadiz</state>
        <zip>11650</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lerida</city>
        <state>Cataluna</state>
        <zip>25198</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torrevieja (Alicante)</city>
        <state>Comunidad Valenciana</state>
        <zip>03186</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>A Coruna</city>
        <state>Galicia</state>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Sebastian de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Alicante</city>
        <zip>03700</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Las Palmas De Gran Canarias</city>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Khon Kaen</city>
        <state>THA</state>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <zip>65000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ubon Ratchathani</city>
        <zip>34000</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Eskisehir</city>
        <state>Meselik</state>
        <zip>26480</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Adana</city>
        <zip>01160</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ankara</city>
        <zip>06490</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Antalya</city>
        <zip>07070</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aydin</city>
        <zip>09100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bursa</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34304</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34662</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35040</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <zip>35340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mersin</city>
        <zip>33343</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sivas</city>
        <zip>58140</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Talas / Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>High Wycombe</city>
        <state>Buckinghamshire</state>
        <zip>HP11 2TT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Stockton on Tees</city>
        <state>Cleveland</state>
        <zip>TS19 8PE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S44 5BL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Craigavon</city>
        <state>Northern Ireland</state>
        <zip>BT63 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wansford</city>
        <state>Peterborough</state>
        <zip>PE8 6PL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Addlestone</city>
        <state>Surrey</state>
        <zip>KT15 2BH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sunderland</city>
        <state>Tyne And Wear</state>
        <zip>SR4 7TP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Leeds</city>
        <zip>LS1 3EX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>York</city>
        <zip>YO31 8HE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Portugal</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Thailand</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Puerto Rico</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/patientsummary/patientsummaries?patientSummaryId=740</url>
    <description>A Plain Language Trial Summary is available on novartisclinicaltrials.com</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 23, 2017</study_first_submitted>
  <study_first_submitted_qc>February 23, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2017</study_first_posted>
  <results_first_submitted>October 26, 2020</results_first_submitted>
  <results_first_submitted_qc>February 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 8, 2021</results_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Diseases</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>Heart failure with Preserved Ejection Fraction</keyword>
  <keyword>NT-proBNP</keyword>
  <keyword>6 MWT</keyword>
  <keyword>KCCQ</keyword>
  <keyword>SF-36</keyword>
  <keyword>NYHA Class</keyword>
  <keyword>LCZ696</keyword>
  <keyword>Enalapril</keyword>
  <keyword>Valsartan</keyword>
  <keyword>Angiotensin-Converting Enzyme Inhibitors (ACEi)</keyword>
  <keyword>Angiotensin II Type 1 Receptor Blockers (ARB)</keyword>
  <keyword>Renin Angiotensin System Inhibitors (RASi)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Enalapril</mesh_term>
    <mesh_term>Enalaprilat</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03066804/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/04/NCT03066804/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 2572 participants were randomized in a 1:1 ratio to receive either sacubitril/valsartan or Individualized Medical Therapy (IMT).</recruitment_details>
      <pre_assignment_details>A total of 2572 participants were randomized in a 1:1 ratio to receive either sacubitril/valsartan or Individualized Medical Therapy (IMT).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sacubitril/Valsartan (LCZ696)</title>
          <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
        </group>
        <group group_id="P2">
          <title>Individualized Medical Therapy (IMT) Comparator</title>
          <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1286"/>
                <participants group_id="P2" count="1286"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1235"/>
                <participants group_id="P2" count="1236"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Technical problems</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Full Analysis Set was the primary efficacy population used in the analyses for all efficacy endpoints and included all randomized patients except 6 patients (5 in sacubitril/valsartan group and 1 in IMT group) excluded due to misrandomization or misstratification.</population>
      <group_list>
        <group group_id="B1">
          <title>Sacubitril/Valsartan (LCZ696)</title>
          <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
        </group>
        <group group_id="B2">
          <title>Individualized Medical Therapy (IMT) Comparator</title>
          <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1281"/>
            <count group_id="B2" value="1285"/>
            <count group_id="B3" value="2566"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="196"/>
                    <measurement group_id="B2" value="221"/>
                    <measurement group_id="B3" value="417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1085"/>
                    <measurement group_id="B2" value="1064"/>
                    <measurement group_id="B3" value="2149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="643"/>
                    <measurement group_id="B2" value="658"/>
                    <measurement group_id="B3" value="1301"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="638"/>
                    <measurement group_id="B2" value="627"/>
                    <measurement group_id="B3" value="1265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1112"/>
                    <measurement group_id="B2" value="1117"/>
                    <measurement group_id="B3" value="2229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12</title>
        <description>To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF</description>
        <time_frame>Baseline, week 12</time_frame>
        <population>Full Analysis Set: This outcome measure represents patients with non-missing change from baseline in log transformed NT-proBNP at Week 12. The model was fitting using change from baseline in log transformed NT-proBNP, and produced a difference in mean change from baseline in log transformed NT-proBNP, which was then transformed back to geometric mean ratio to baseline using an exponential transformation.</population>
        <group_list>
          <group group_id="O1">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
          </group>
          <group group_id="O2">
            <title>Individualized Medical Therapy (IMT) Comparator</title>
            <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) at Week 12</title>
          <description>To demonstrate that LCZ696 is superior to individualized medical therapy for comorbidities in reducing NT-proBNP from baseline at Week 12 in patients with HFpEF</description>
          <population>Full Analysis Set: This outcome measure represents patients with non-missing change from baseline in log transformed NT-proBNP at Week 12. The model was fitting using change from baseline in log transformed NT-proBNP, and produced a difference in mean change from baseline in log transformed NT-proBNP, which was then transformed back to geometric mean ratio to baseline using an exponential transformation.</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1203"/>
                <count group_id="O2" value="1216"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8218" lower_limit="0.7955" upper_limit="0.8489"/>
                    <measurement group_id="O2" value="0.9828" lower_limit="0.9515" upper_limit="1.0151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Week 12</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.8362</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.7987</ci_lower_limit>
            <ci_upper_limit>0.8754</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24</title>
        <description>Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.</description>
        <time_frame>Baseline, week 24</time_frame>
        <population>Subset of Full Analysis Set: This outcome measure was analyzed on patients with a Baseline 6MWD from 100 meters to 450 meters.</population>
        <group_list>
          <group group_id="O1">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
          </group>
          <group group_id="O2">
            <title>Individualized Medical Therapy (IMT) Comparator</title>
            <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 6 Minute Walk Distance (6MWD) at Week 24</title>
          <description>Change from baseline in 6-minute walk distance (6MWD) will be reported at Week 24. The 6 MWT will be performed in accordance with the guidelines of the American Thoracic Society 2002.</description>
          <population>Subset of Full Analysis Set: This outcome measure was analyzed on patients with a Baseline 6MWD from 100 meters to 450 meters.</population>
          <units>Meters</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1082"/>
                <count group_id="O2" value="1075"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6935" lower_limit="5.4310" upper_limit="13.9559"/>
                    <measurement group_id="O2" value="12.1920" lower_limit="7.9202" upper_limit="16.4638"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4164</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.4985</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.5267</ci_lower_limit>
            <ci_upper_limit>3.52297</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24</title>
        <description>The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full Analysis Set: This outcome measure represents patients with both baseline KCCQ Clinical Symptom Scores (CSS) and Week 24 KCCQ CSS observed and non-missing covariates.</population>
        <group_list>
          <group group_id="O1">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
          </group>
          <group group_id="O2">
            <title>Individualized Medical Therapy (IMT) Comparator</title>
            <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) at Week 24</title>
          <description>The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
          <population>Full Analysis Set: This outcome measure represents patients with both baseline KCCQ Clinical Symptom Scores (CSS) and Week 24 KCCQ CSS observed and non-missing covariates.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1207"/>
                <count group_id="O2" value="1210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3399" lower_limit="11.3151" upper_limit="13.3647"/>
                    <measurement group_id="O2" value="11.8168" lower_limit="10.7922" upper_limit="12.8415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4791</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.5231</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.9258</ci_lower_limit>
            <ci_upper_limit>1.9720</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24</title>
        <description>Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full Analysis Set: This outcome measure represents patients with both baseline KCCQ Clinical Symptom Scores (CSS) and Week 24 KCCQ CSS observed and non-missing covariates.</population>
        <group_list>
          <group group_id="O1">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
          </group>
          <group group_id="O2">
            <title>Individualized Medical Therapy (IMT) Comparator</title>
            <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With ≥ 5-points Deterioration in KCCQ Clinical Symptom Score(CSS) at Week 24</title>
          <description>Percentage of patients with KCCQ CSS deterioration ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
          <population>Full Analysis Set: This outcome measure represents patients with both baseline KCCQ Clinical Symptom Scores (CSS) and Week 24 KCCQ CSS observed and non-missing covariates.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1207"/>
                <count group_id="O2" value="1210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.49"/>
                    <measurement group_id="O2" value="16.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5294</p_value>
            <method>longitudinal binary logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8993</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6461</ci_lower_limit>
            <ci_upper_limit>1.2518</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24</title>
        <description>Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full Analysis Set: This outcome measure represents patients with both baseline KCCQ Clinical Symptom Scores (CSS) and Week 24 KCCQ CSS observed and non-missing covariates.</population>
        <group_list>
          <group group_id="O1">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
          </group>
          <group group_id="O2">
            <title>Individualized Medical Therapy (IMT) Comparator</title>
            <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With ≥ 5-points Improvement in KCCQ Clinical Symptom Score(CSS) at Week 24</title>
          <description>Percentage of patients with KCCQ CSS improvement ≥ 5-points will be reported at Week 24. The KCCQ is a self-administered questionnaire that requires 4 to 6 minutes to complete. It contains 23 items, covering physical function, clinical symptoms, social function, self-efficacy and knowledge, and Quality of Life (QoL). The CSS is a combined score based upon the clinical symptoms and physical function domains of the questionnaire. Scores are transformed to a range of 0 - 100, in which higher scores reflect better health status.</description>
          <population>Full Analysis Set: This outcome measure represents patients with both baseline KCCQ Clinical Symptom Scores (CSS) and Week 24 KCCQ CSS observed and non-missing covariates.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1207"/>
                <count group_id="O2" value="1210"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.94"/>
                    <measurement group_id="O2" value="65.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4938</p_value>
            <method>longitudinal binary logistic regression</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1060</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8287</ci_lower_limit>
            <ci_upper_limit>1.4760</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in NYHA Functional Class at Week 24</title>
        <description>NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time.&#xD;
Class I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest&#xD;
The NYHA class change will be analyzed as a three category ordinal variable with levels: &quot;improved&quot;, &quot;unchanged&quot;, and &quot;worsened&quot;, defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.</description>
        <time_frame>Baseline, week 24</time_frame>
        <population>Full Analysis Set: This outcome measure represents patients with both a baseline NYHA class and NYHA class at the visit observed.</population>
        <group_list>
          <group group_id="O1">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
          </group>
          <group group_id="O2">
            <title>Individualized Medical Therapy (IMT) Comparator</title>
            <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in NYHA Functional Class at Week 24</title>
          <description>NYHA classification is a subjective physician's assessment of patient's functional capacity and symptomatic status and can change frequently over time.&#xD;
Class I - No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF Class II - Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF Class III - Marked limitation of physical activity. Comfortable at rest, but less than ordinary activity causes symptoms of HF Class IV - Unable to carry on any physical activity without symptoms of HF, or symptoms of HF at rest&#xD;
The NYHA class change will be analyzed as a three category ordinal variable with levels: &quot;improved&quot;, &quot;unchanged&quot;, and &quot;worsened&quot;, defined by at least one class improvement, no change, at least one class worsening, in NYHA class, respectively.</description>
          <population>Full Analysis Set: This outcome measure represents patients with both a baseline NYHA class and NYHA class at the visit observed.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1228"/>
                <count group_id="O2" value="1229"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.62"/>
                    <measurement group_id="O2" value="24.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.23"/>
                    <measurement group_id="O2" value="71.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.15"/>
                    <measurement group_id="O2" value="4.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8314</p_value>
            <method>Proportional cumulative odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9798</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8122</ci_lower_limit>
            <ci_upper_limit>1.1820</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24</title>
        <description>The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 &quot;worst&quot;-100 &quot;best&quot;).</description>
        <time_frame>Baseline, Week 24</time_frame>
        <population>Full Analysis Set: This outcome measure represents patients with non-missing change from baseline in SF-36 PCS at Week 24.</population>
        <group_list>
          <group group_id="O1">
            <title>Sacubitril/Valsartan (LCZ696)</title>
            <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
          </group>
          <group group_id="O2">
            <title>Individualized Medical Therapy (IMT) Comparator</title>
            <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in The Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24</title>
          <description>The SF-36 PCS score reflects the measure of quality of life based on the 36 questions which evaluate the person's physical, emotional, and mental status, including general health. Specifically, the SF-36 PCS score focuses on assessing the person's physical status. The score ranges from 0 to 100 with a higher score indicating a better status of physical wellbeing (range = 0 &quot;worst&quot;-100 &quot;best&quot;).</description>
          <population>Full Analysis Set: This outcome measure represents patients with non-missing change from baseline in SF-36 PCS at Week 24.</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1185"/>
                <count group_id="O2" value="1191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5405" lower_limit="2.0787" upper_limit="3.0023"/>
                    <measurement group_id="O2" value="2.6975" lower_limit="2.2360" upper_limit="3.1590"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6370</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1570</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.8093</ci_lower_limit>
            <ci_upper_limit>0.4953</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from first dose of study treatment until end of study treatment plus 30 days post treatment, up to maximum duration of approx. 2 years.</time_frame>
      <desc>Any sign or symptom that occurs during the study treatment plus the 30 days post treatment. AEs were collected and analyzed based on the treatment arm (LCZ696 vs IMT) which the patient was randomized to, regardless of dose level. Hence no dose-specific analysis were performed. Eight patients were excluded from enrolled set [2572], as they did not receive any study treatment (6 patients in the LCZ696 arm and 2 patients in the IMT arm).</desc>
      <group_list>
        <group group_id="E1">
          <title>Sacubitril/Valsartan (LCZ696)</title>
          <description>All patients who fulfilled the inclusion/exclusion criteria were stratified before randomization based upon prior therapy for comorbidities to one of 3 strata: ACEi, ARB or no RASi.</description>
        </group>
        <group group_id="E2">
          <title>Individualized Medical Therapy (IMT)</title>
          <description>Patients randomized to the comparator arm received either enalapril (ACE stratum) valsartan (ARB stratum) or LCZ696 matching placebo (no RASi stratum).</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="40" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="186" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="191" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="377" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="52" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiac perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cor pulmonale acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Dressler's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Sinus arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Mitochondrial myopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Vestibular ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Iris neovascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Macular hole</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Retinal artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Haemorrhagic erosive gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Incarcerated inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Mallory-Weiss syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Generalised oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hepatic congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cutaneous leishmaniasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="26" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Post procedural sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Agitation postoperative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Fractured sacrum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>International normalised ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Diabetic metabolic decompensation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Colon adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Gastrointestinal carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Nasal cavity cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Neuroendocrine tumour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Oesophageal squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Rectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Renal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Spinal meningioma benign</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Urinary tract neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carotid artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Haemorrhagic transformation stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hepatic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypoxic-ischaemic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Alcohol abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Diabetic nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Nephritic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Chronic respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pulmonary hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Accelerated hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Arterial rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypertensive urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Iliac artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Peripheral vascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (22.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="964" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="832" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="1796" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="85" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="78" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="64" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="84" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Glomerular filtration rate decreased</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="150" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="287" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Urine albumin/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="157" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="254" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Urine protein/creatinine ratio increased</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="131" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="138" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="286" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="63" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="48" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="145" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="104" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="249" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="45" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="84" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="205" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="148" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="258" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="93" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="123" subjects_at_risk="2564"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="176" subjects_at_risk="1280"/>
                <counts group_id="E2" subjects_affected="69" subjects_at_risk="1284"/>
                <counts group_id="E3" subjects_affected="245" subjects_at_risk="2564"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

